Proteins & Protein Crystals Market

The global proteins & protein crystals market is projected to reach USD 960.37 billion by 2030 from USD 609.51 billion in 2025, at a CAGR of 9.5%. The growth of the market is driven by the surging demand for high-purity proteins across pharmaceuticals, food processing, and biotechnology. Increasing chronic disease prevalence and the need for advanced drug discovery platforms continue to accelerate adoption.

Rapid advancements in automation, structural biology, and crystallization technologies—combined with increased R&D investments in therapeutic and industrial proteins—are further fuelling market expansion. Leading companies shaping the protein and protein crystals landscape include Amgen (US), Roche (Switzerland), Danaher (US), Merck KGaA (Germany), Eli Lilly and Company (US), Novo Nordisk A/S (Denmark), Pfizer Inc. (US), Bristol-Myers Squibb Company (US), Thermo Fisher Scientific Inc. (US), and Associated British Foods plc (UK), among others.

To know about the assumptions considered for the study download the pdf brochure

Danaher (US)

Danaher manufactures and markets medical, industrial, and other products and services. Danaher has three business segments: Life Sciences, Biotechnology, and Diagnostics. Danaher operates through three primary segments: Life Sciences, Diagnostics, and Biotechnology. Its focus on continuous innovation, digital integration, and process automation strengthens its position as a major contributor to advancements in protein structure determination and bioprocessing efficiency. Key subsidiaries of the company include AB SCIEX (US), HemoCue AB (Sweden), Beckman Coulter, Inc. (US), Leica Biosystems (Germany), Leica Microsystems (Germany), Pall Corporation (US), Molecular Devices, LLC (US), and Radiometer Medical ApS (Denmark). Danaher maintains a broad global footprint, with offices, facilities, and operations spanning multiple countries across North and South America, Europe, Asia, and the Middle East.

Amgen (US)

Amgen is a leading biotechnology company specializing in protein-based therapeutics, including monoclonal antibodies and other biologics. Its expertise in protein engineering, biologics manufacturing, and structural biology makes it a major user of high-purity proteins, crystallization tools, and protein characterization technologies. By leveraging advanced platforms, including AI-driven protein design, Amgen drives demand for protein production and crystallization services, supporting the development of novel therapeutics across oncology, inflammation, rare diseases, and metabolic disorders.

Merck KGaA (Germany)

Merck KGaA is a global leader in life sciences reagents and tools, offering one of the broadest portfolios of proteins, enzymes, recombinant proteins, and biochemistry reagents used for everything from basic research to drug development and bioprocessing. Its catalog spans high-purity enzymes (glycosidases, proteases, nucleases, kinases, etc.), extracellular-matrix and adhesion proteins, growth factors and recombinant proteins all critical for structural biology, protein crystallization, functional assays, and downstream biologics development. By supplying these reagents along with sample-preparation kits, purification materials (e.g., chromatography resins), detection platforms, and custom/bulk-supply services, Merck helps research labs, biotech firms, and pharma companies accelerate protein-based research and biologics manufacturing.

Its global footprint (serving customers in 66+ countries with 300,000+ life-science products) and investments in R&D and manufacturing infrastructure position it as a backbone supplier in the protein & protein-crystals ecosystem.

Market Ranking:

The proteins & protein crystals market is moderately fragmented but primarily led by several key players—Danaher, Merck, Amgen, Eli Lilly, Roche, Novo Nordisk, Pfizer, Bristol-Myers Squibb (BMS), Thermo Fisher Scientific, and Associated British Foods—who dominate with extensive product portfolios and strong global presence. Roche holds the largest market share, estimated at around 18–20%, driven by its broad offerings in protein analysis, purification, and crystallization solutions. Thermo Fisher Scientific follows with approximately 10–15% of the market, leveraging its comprehensive portfolio of high-purity proteins, enzymes, and innovative crystallography tools that accelerate drug discovery and biologics development. Amgen commands about 10–12%, fuelled by its demand for high-quality proteins and advanced protein engineering technologies in biologics manufacturing. Other notable participants, such as Eli Lilly, Danaher, Novo Nordisk, Pfizer, and Bristol-Myers Squibb, collectively hold the remaining 65-70% of the market, innovating in protein crystallization techniques and expanding applications across healthcare, agriculture, and industrial biotechnology.

Related Reports:

Proteins & Protein Crystals Market by Product Type (Enzyme, Monoclonal Antibodies, Insulin, Hormones); Structural (Membrane, Matrix); Specialty (Nutrition, Analytics, Cosmetics); Application (Healthcare, Environmental); End User (Pharma, Biotech, CROs)

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com